Acadian Asset Management LLC Savara Inc Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$1.17 - $2.33 $33,707 - $67,127	-28,810 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$1.0 - $1.47 $173,315 - $254,773	-173,315 Reduced 85.75%	28,810 $33,000
Q3 2020 Nov 09, 2020	SELL	$1.09 - $2.21 $36,161 - $73,318	-33,176 Reduced 14.1%	202,125 $220,000
Q2 2020 Aug 12, 2020	BUY	$1.8 - $3.05 $21,834 - $36,996	12,130 Added 5.44%	235,301 $586,000
Q1 2020 May 11, 2020	BUY	$1.91 - $4.08 $260,820 - $557,144	136,555 Added 157.66%	223,171 $474,000

Q4 2019 Feb 06, 2020	BUY	$0.71 - $4.91 $61,497 - $425,284	86,616 New	86,616 $388,000

122

121M

123K

14.7K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $552M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.